Recently, a domestic biopharmaceutical equipment company, in collaboration with a university’s School of Pharmacy, has successfully developed a specialized laboratory reactor tailored for the biopharmaceutical field. By integrating precise biocompatibility control and multi-parameter cooperative regulation technologies, the equipment addresses common issues in traditional reactors—such as ingredient inactivation and low yield during the synthesis of bioactive substances—providing essential experimental support for innovative drug development and potentially shortening R&D timelines for biologics.

　　According to the R&D team, the synthesis of bioactive pharmaceutical ingredients—such as peptides, enzyme preparations, and natural active extracts—requires extremely strict control over environmental factors including temperature, pH, oxygen concentration, and stirring rate. Conventional laboratory reactors often lead to degradation or structural alteration of active ingredients due to insufficient temperature control accuracy and poor material compatibility with biological reagents, significantly reducing synthesis yields.

　　The newly introduced biopharmaceutical reactor features a medical-grade 316L stainless steel inner vessel with a polytetrafluoroethylene (PTFE) composite coating, ensuring full compatibility with biological reagents without adverse reactions. Its nano-level temperature control system enhances temperature precision to ±0.1°C, while integrated online pH monitoring and automatic acid-base adjustment modules maintain system stability in real time. In tests involving the synthesis of peptide drug intermediates, the reactor achieved a target product yield of 92.5%—a 25% improvement over conventional equipment—with bioactive retention rates exceeding 98%. In enzymatic reaction experiments, process duration was shortened by 40%, and enzyme activity loss was reduced to below 5%.

　　“This reactor fills a gap in the domestic availability of specialized laboratory reaction equipment for biopharmaceutical applications, offering a more efficient experimental tool for early-stage drug innovation in universities, research institutes, and pharmaceutical companies,” stated Professor Wang Lei, the project lead from the School of Pharmacy. To date, five biopharmaceutical companies have signed cooperation agreements to deploy the reactor in preclinical R&D for anti-tumor and antiviral drug candidates. Small-batch industrial production is anticipated next year, with the system gradually entering more drug development laboratories.